Merck/Portola's betrixaban shows bleeding benefit in Phase IIb
This article was originally published in Scrip
Executive Summary
Merck/ Portola Pharmaceuticals' investigational Factor Xa inhibiting anticoagulant betrixaban was associated with significantly less clinically relevant bleeding than warfarin when given at 40mg/day to patients with atrial fibrillation, show new results from a dose-finding study presented on March 15th at the American College of Cardiology (ACC) meeting in Atlanta.